Search Results - "Henney, Herbert R"

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis by Blight, Andrew R., Henney III, Herbert R., Cohen, Ron

“…Walking impairment is a clinical hallmark of multiple sclerosis (MS). Dalfampridine‐ER, an extended‐release formulation of dalfampridine (also known by its…”
Get full text

Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease by Safirstein, Beth E., Ellenbogen, Aaron, Zhao, Ping, Henney, Herbert R., Kegler-Ebo, Deena M., Oh, Charles

“…Levodopa (LD) is the most effective oral pharmacotherapy for the management of motor symptoms in Parkinson's disease. However, LD use is complicated by a…”
Get full text

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis by Weir, Scott, Torkin, Risa, Henney III, Herbert R.

“…Abstract Background In January 2010, dalfampridine extended release tablets (dalfampridine-ER [Ampyra*]; prolonged-, modified- or sustained-release fampridine…”
Get full text

Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trial by Vollmer, Timothy, MD, Henney, Herbert R., PharmD

“…Abstract Background: Fampridine (4-aminopyridine) is a potassium channel-blocking agent that has been reported to have therapeutic potential for improving…”
Get full text

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study by Vollmer, Timothy, MD, Blight, Andrew R., PhD, Henney, Herbert R., PharmD

“…Abstract Background: Fampridine sustained release (SR) has generally been well tolerated in clinical studies in patients with multiple sclerosis (MS) at doses…”
Get full text

Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study by Samara, Emil, Winkle, Peter, Pardo, Patricia, Henney III, Herbert R., Way, Susan L., Brown, Eppie, Lee, Angela, Blight, Andrew R.

“…Dalfampridine extended release tablets (D‐ER; prolonged‐release fampridine in Europe) are available to improve walking in patients with multiple sclerosis…”
Get full text

Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults by Henney, Herbert R, Sperling, Michael R, Rabinowicz, Adrian L, Bream, Gary, Carrazana, Enrique J

“…Highlights • Bioavailability was comparable between intranasal and rectal gel diazepam. • High (20 mg) and low (5 mg) doses of intranasal diazepam were dose…”
Get full text

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US by Jara, Michele, Barker, Graham, Henney, 3rd, Herbert R

“…Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved in the US to…”
Get full text

Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy by Sperling, Michael R., Haas, Kevin F., Krauss, Gregory, Seif Eddeine, Hussam, Henney, Herbert R., Rabinowicz, Adrian L., Bream, Gary, Squillacote, David, Carrazana, Enrique J.

“…Summary Objective To determine the feasibility of administering a diazepam nasal spray formulation (diazepam‐NS) to adults with epilepsy during a generalized…”
Get full text

Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers by Henney, 3rd, Herbert R, Faust, Bonnie, Blight, Andrew R

“…The pharmacokinetics, bioavailability, and tolerability of dalfampridine extended-release tablets in healthy adults under fed and fasted conditions were…”
Get full text

Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis by Weir, Scott, Gao, Yuying, Henney, Herbert R.

“…Abstract Objective: Using data pooled from several studies of dalfampridine extended release (ER), a population pharmacokinetic model was developed for the…”
Get full text

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis by Kantor, Daniel, Chancellor, Michael B., Snell, Clayton W., Henney III, Herbert R., Rabinowicz, Adrian L.

“…Urinary tract infections (UTIs) were reported frequently with dalfampridine extended-release (dalfampridine-ER) 10 mg relative to placebo in previous multiple…”
Get full text

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials by Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R, Agius, M, Arnason, BGW, Bethoux, FA, Bever, CT, Bowen, JD, Brown, TR, Dietrich, DW, Edwards, K, Freedman, MS, Freedman, M, Kachuck, NJ, Kaufman, MD, Keilson, M, Khan, O, Krupp, LB, Leist, TP, Lindsey, JW, Lublin, FD, Mass, MK, Mattson, D, McGowan, D, Naismith, R, O’Connell, C, Oger, JJ, Panitch, H, Picone, MA, Rammohan, KW, Schapiro, RT, Schwid, SR, Scott, T, Short, C, Thrower, BW, Vollmer, TL, Camac, A, Cooper, JA, Chumley, WF, Cross, A, Dunnigan, RT, Gitt, JS, Hillen, M, Jeffrey, DR, Khatri, BO, Kresa-Reahl, K, Moon, S, Preiningerova, J, Tullman, M, Weinstock-Guttman, B, Wynn, DR

“…Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release…”
Get full text

A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury by Kamen, Leonard, Henney, Herbert R., Runyan, Jacob D.

“…ABSTRACT Objective: Tizanidine is an imidazoline central α2-adreno­ceptor agonist widely used to manage spasticity secondary to conditions such as multiple…”
Get full text

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis by Jara, Michele, Sidovar, Matthew F, Henney, 3rd, Herbert R

“…This study aimed to characterize the prescribing of dalfampridine extended release (D-ER) 10 mg tablet treatment in people with multiple sclerosis (MS). A…”
Get full text

Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: A single-dose, randomized, open-label, crossover study in healthy subjects by Henney, Herbert R., PharmD, Shah, Jaymin, PhD

“…Abstract Background: An immediate-release, multiparticulate capsule formulation of tizanidine has been developed to modify tizanidine pharmacokinetic…”
Get full text

Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: A single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects by Henney, Herbert R., PharmD, Fitzpatrick, Anthony, MB, Stewart, Johnston, MB, MRCGP, Runyan, Jacob D., MSc

“…Abstract Background: The α2-adrenergic agonist tizanidine has been reported to have a narrow therapeutic index. A multiparticulate capsule formulation of…”
Get full text

Pediatric Safety of Tizanidine: Clinical Adverse Event Database and Retrospective Chart Assessment by Henney, Herbert R., Chez, Michael

“…Background: Tizanidine is an imidazoline with central α 2 -adrenoceptor agonist activity at both spinal and supraspinal levels, which is indicated as a…”
Get full text

Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis by Fjeldstad, Cecilie, Suárez, Gustavo, Klingler, Michael, Henney, 3rd, Herbert R, Rabinowicz, Adrian L, Pardo, Gabriel

“…Dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS), as demonstrated by walking speed improvement. This exploratory…”
Get full text

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial by Yapundich, Robert, Applebee, Angela, Bethoux, Francois, Goldman, Myla D, Hutton, George J, Mass, Michele, Pardo, Gabriel, Klingler, Michael, Henney, 3rd, Herbert R, Blight, Andrew R, Carrazana, Enrique J

“…Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety…”
Get full text